Boceprevir and Telaprevir Near FDA Approval: Will Quickly Change HCV Development Rules
This article was originally published in RPM Report
The upcoming launch of two new hepatitis C therapies will be one of the biggest biopharmaceutical stories of 2011. But FDA’s antiviral regulatory group is keen to make sure that is only the first chapter in a long story of advances in treatment in the class.
You may also be interested in...
Roche presented a mixed sales picture across regions and products in a first quarter 2012 earnings call. Management highlighted a busy regulatory quarter with two new NME launches and five positive Phase III trials and filings, but also reported generic and competitive threats to key products.
With perhaps little over a year to go before it files its NDA for hepatitis C hopeful telaprevir, Vertex is gearing up for its transition to a commercially focused company. New CEO Matt Emmens talks to IN VIVO about the financial and cultural challenges of building a commercial organization to match Vertex's highly productive R&D.
As Big Pharma finds itself searching for products in smaller, more specialist markets, biotechs must decide whether it is better to take a product to market alone and reap the rewards while dealing with the risks, or take the money and run. Such is the happy dilemma for biotechs developing new drugs for HCV, an exploding market blessed with quick development timeframes and early proof-of-concept potential.